IUPAC: 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine · MW 162.23 g/mol · CAS 54-11-5 · C₁₀H₁₄N₂
(S)-Nicotine. Plant-defense pyridine alkaloid from Nicotiana tabacum · the single most reinforcing legal drug in wide human use · delivered by combustion (cigarette), aerosol (vape), buccal/transdermal (gum, patch, pouch). The drug people are dependent on is not the thing that kills them.
Nicotine is an agonist at nicotinic acetylcholine receptors (nAChRs) — pentameric ligand-gated cation channels. Its high-affinity CNS target is the α4β2 subtype, where it binds the acetylcholine orthosteric site at the α/β subunit interface, drives the channel open, and admits Na⁺ and Ca²⁺. It is not a monoamine transporter ligand like cocaine or MDMA; it acts on an ionotropic receptor directly, upstream of the dopamine system it ultimately hijacks.
The defining feature of nicotinic pharmacology is the three-state cycle: resting (closed), open (conducting), and desensitized (agonist-bound but shut). Nicotine's ~1 nM binding Ki at α4β2 largely reflects affinity for the desensitized high-affinity state — which is why the concentration that opens the channel (EC50 ~1 µM) is roughly a thousand-fold higher than the binding constant. A smoker's plasma sits in a range that keeps a large fraction of α4β2 receptors desensitized most of the day.
Nicotine occupies the ACh pocket at the α4(+)/β2(−) interface — aromatic box (Trp, Tyr) plus a cation-π contact to the protonated pyrrolidine — gating Na⁺/Ca²⁺ influx and neuronal depolarization.
Within seconds to minutes, agonist-occupied α4β2 collapses into a non-conducting, high-affinity desensitized state. Much of chronic nicotine's CNS action is functional receptor silencing, not tonic activation.
Chronic exposure paradoxically increases α4β2 binding-site density. Nicotine acts as a pharmacological chaperone, stabilizing assembly/trafficking of high-sensitivity (α4)₂(β2)₃ pentamers — the structural substrate of withdrawal and craving.
α4β2 on VTA dopamine neurons boosts burst firing; α7 on glutamate terminals adds excitatory drive; desensitization of α4β2 on GABA interneurons disinhibits. Net effect: phasic dopamine in nucleus accumbens → reinforcement.
Low-affinity α7 (Ca²⁺-permeable, fast-desensitizing) shapes plasticity; α3β4 in autonomic ganglia and adrenal medulla mediates the cardiovascular / sympathetic effects — catecholamine release, ↑HR, ↑BP.
~2 h parent t½ means levels fall between doses; receptors resensitize, and the next dose re-opens the reward loop. The stimulus/withdrawal rhythm — not a long steady state — is what entrenches the habit.
Inhaled nicotine reaches the brain in 10–20 seconds as a high arterial bolus — faster than intravenous injection. That speed, not the peak concentration, is the pharmacological engine of dependence: tight temporal contiguity between the act (a puff) and the dopamine signal is close to an optimal reinforcement schedule.
Nicotine is a diprotic base (pyridine N pKa ≈ 3.1; pyrrolidine N pKa ≈ 8.0). Only the uncharged free base crosses membranes readily, so absorption is exquisitely pH-dependent. Cigarette smoke is mildly acidic (pH ~5.5–6), so little is absorbed in the mouth — it must reach the huge alveolar surface of the lung, where it enters arterial blood almost instantly. Cigar and pouch products, and "freebased" e-liquids, shift pH up to enable buccal absorption. This is why delivery route and formulation pH, not just nicotine content, determine the addiction profile.
Metabolism cascade: ~70–80% of nicotine is C-oxidized by hepatic CYP2A6 (via the nicotine-Δ1′(5′)-iminium ion, then aldehyde oxidase) to cotinine, then further hydroxylated to trans-3′-hydroxycotinine. Minor routes include N-glucuronidation (UGT2B10) and N′-oxidation (FMO3).
Cotinine (marked ★) has a much longer half-life (~16–19 h) and is the standard biomarker of tobacco/nicotine exposure. The ratio trans-3′-hydroxycotinine / cotinine — the Nicotine Metabolite Ratio (NMR) — is a validated phenotypic readout of CYP2A6 activity.
CYP2A6 is highly polymorphic. Slow metabolizers (common reduced-function alleles, notably frequent in East Asian populations) clear nicotine sluggishly, maintain higher levels per cigarette, tend to smoke fewer cigarettes, and show different quit-success profiles. Fast metabolizers clear nicotine quickly, redose more, and respond better to higher-dose or non-patch NRT. Nicotine also modestly induces CYP1A2 (via tobacco-smoke polycyclic aromatics, not nicotine itself) — which is why smokers often need higher doses of CYP1A2 substrates such as clozapine, olanzapine, or caffeine, and why those levels rise on quitting.
Nicotine's subjective effect is modest — mild arousal, sharpened attention, reduced appetite, a small anxiolytic-then-relief profile — yet its dependence liability is among the highest of any drug. The dissociation is the point: nicotine is not intensely euphoric; it is intensely reinforcing, because delivery is fast, repeatable hundreds of times a day, and coupled tightly to phasic dopamine.
α4β2 receptors on VTA dopaminergic neurons increase phasic burst firing, elevating dopamine in the nucleus accumbens shell. β2-knockout animals do not self-administer nicotine — the β2 subunit is necessary for reinforcement. This is the shared final common path of essentially all addictive drugs, reached here through an ion channel rather than a transporter.
nAChR activation across cortex, thalamus, and basal forebrain sharpens signal-to-noise in attention and working-memory circuits — the genuine cognitive "hit" smokers report. Much of the day-to-day benefit, however, is relief of withdrawal-induced deficits rather than enhancement above a never-smoker baseline.
The medial habenula–interpeduncular axis, rich in α3β4/α5 receptors, encodes nicotine aversion and satiety — a brake on intake. The CHRNA5 variant (rs16969968) weakens this brake and is one of the most robust human genetic associations with heavy smoking and lung-cancer risk. Dependence is a balance between accumbal "go" and habenular "stop".
On abstinence, upregulated/resensitized receptors and a hypodopaminergic accumbens produce irritability, anxiety, restlessness, impaired concentration, increased appetite, and craving — peaking 1–3 days, largely resolving over 2–4 weeks. Late relapse is driven more by cue-conditioned craving than by residual physical withdrawal. Most of chronic smoking is negative reinforcement: dosing to abolish withdrawal, not to get high.
Pharmacotherapies map directly onto this biology: NRT supplies agonist without combustion; varenicline is a high-affinity α4β2 partial agonist (blunts reward while easing withdrawal); bupropion adds dopaminergic/noradrenergic tone plus weak nAChR antagonism; cytisine, a plant partial agonist, does the same cheaply.
Non-moralistic and mechanistic. The central fact of nicotine harm reduction: people smoke for the nicotine but die from the smoke. Tobacco combustion generates tar, carbon monoxide, oxidant gases, particulate, polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines — that mixture drives the lung cancer, COPD, and most of the cardiovascular death. Nicotine itself is the reinforcing agent, not the principal carcinogen. Separating the drug from the delivery system is where nearly all the risk reduction lives.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
α4β2
Neuronal nAChR α4/β2 (CHRNA4/CHRNB2)
|
Ki ≈ 1 nM
EC₅₀ ~1 µM (function)
|
Agonist | |
|
α3β4
Ganglionic nAChR α3/β4
|
Ki ≈ 320–530 nM
|
Agonist | |
|
α4β4
Neuronal nAChR α4/β4
|
Ki ~40–120 nM
|
Agonist | |
|
α7
Homomeric nAChR α7 (CHRNA7)
|
Ki ≈ 0.5–4 µM
EC₅₀ ~13–100 µM
|
Low-aff. agonist | |
|
Muscle
Muscle-type nAChR α1β1δε
|
Ki > 1 µM (weak)
|
Partial / weak |
Nicotine is a rigid ligand — one rotatable bond linking pyridine to pyrrolidine (ChEMBL: RTB = 1). It pays a small conformational-entropy penalty on binding, because there is almost no torsional freedom to freeze out. That rigidity is a large part of why a 162 Da molecule can hit ~1 nM: the aromatic box (Trp149/Tyr) forms a cation-π clamp on the protonated pyrrolidinium while the pyridine N accepts a backbone H-bond, and the small ligand loses little translational/rotational freedom relative to the enthalpy gained.
In FlexAID∆S terms, the informative ΔS is on the receptor side: agonist binding drives loop-C capping over the pocket and the resting→desensitized isomerization — a global collapse of the pentamer's accessible conformational microstates (a Shannon-entropy contraction). The ~1000× gap between binding Ki (~1 nM) and gating EC₅₀ (~1 µM) is exactly this: tight affinity is dominated by the low-entropy desensitized well, not by the transient open state.